The ups and downs of multiple sclerosis therapeutics

Annals of Neurology

Volumn 49, Issue 3, 2001, Pages 281-284

  Hohlfeld, Reinhard ^a,b   Wiendl, Heinz ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AG 284; AL 100; AUTOANTIGEN; CGP 77116; CLADRIBINE; GLATIRAMER; HLA DR2 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON BETA SERINE; LENERCEPT; LIGAND; MITOXANTRONE; MYELIN BASIC PROTEIN; MYLORAL; PEPTIDE; RECOMBINANT INTERLEUKIN 10; ROQUINIMEX; SALAZOSULFAPYRIDINE; T LYMPHOCYTE RECEPTOR; TIPLIMOTIDE; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DEMYELINATING DISEASE; DRUG BIOAVAILABILITY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; EDITORIAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

HUMANS; MULTIPLE SCLEROSIS;

EID: 0035092524     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.61     Document Type: Editorial

References (34)

1. The European/Canadian Multicenter, double blind, randomized, placebo controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
3. The role of magnetic resonance techniques in understanding and managing multiple sclerosis
4. Multiple sclerosis: Comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
5. Glatiramet acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
6. Mechanisms of immunomodulation by glatiramer acetate
7. Mechanisms of action of glatiramer acetate in multiple sclerosis
8. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells
9. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy
10. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: A neuroprorective role of inflammation?
11. The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis
12. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
13. Induction of a nonencephalitogenic type 2 T-helper cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized phase II trial
14. A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis
15. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis
16. MRI results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis
17. Clinical results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis
18. Depletion of myelinbasic-protein autoreactive T cells by T-cell vaccination: Pilot trial in multiple sclerosis
19. Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial
20. TNF neutralization in MS - Results of a randomized, placebo controlled multicenter study
21. Linomide in relapsing and secondary progressive MS: Part I: Trial design and clinical results
22. Linomide in relapsing and secondary progressive MS: Parr II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators
23. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active mul tiple sclerosis
24. Deoxyspergualine in the treatment of active MS: Final analysis of the European multicenter study
25. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
26. The effect of cladribine on T(1) "black hole" changes in progressive MS
27. Whole brain volume changes in patients with progressive MS treated with cladtibine
28. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
29. Phasetrial of transforming-growth-factor-beta-2 in chronic progressive MS
30. Immunoglobulin administration does not reverse visual-acuity loss in long-standing optic neuritis associated with multiple sclerosis
31. Multiple Sclerosis (MS) disease activity may determine whether immunoglobulin (IVIg) administration enhances or worsens visual function in patients with severe, stable optic neuritis (SDON)
32. IV immunoglobulin does not reverse established weakness in MS: A double-blind, placebo-controlled trial
33. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis
34. Genetic models for CNS inflammation